- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04630223
Levels of Endocan in Umbilical Cord Blood Samples of Pregnant Females With Intrauterine Growth Retardation
Comparison of Umbilical Cord Blood Levels of Endocan in Pregnant Females With and Without Intrauterine Growth Retardation
As a proteoglycan secreted from endothelial cells, expression, and secretion of endocan increases in the endothelium of several tissues secondary to inflammation. It can be regarded as an indicator of endothelial damage. Besides, it is both a target and a modulator of the vascular endothelial growth factor (VEGF) signaling pathway. Considering its action mechanisms, it can provide information about angiogenesis, inflammation, and vascular permeability.
It is known that intrauterine growth retardation mainly occurs as a result of endothelial dysfunction and abnormal angiogenesis in the placenta. In previous studies, maternal serum endocan levels have also been shown to be increased in cases of preeclampsia, which is mainly characterized by placental dysfunction.So, we hypothesize that there may be an association between endocan levels and intrauterine growth retardation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Endocan is a proteoglycan that is closely associated with inflammation. Its levels increase in association with the severity of endothelial damage. Endothelial dysfunction and abnormal angiogenesis in the placental tissues are the main pathophysiological mechanisms leading to intrauterine growth retardation.
It has been known that there was a significant association between maternal serum levels of endocan and preeclampsia. In cases with preeclampsia, increased serum levels of endocan in maternal blood samples has been reported.
Intrauterine growth retardation is a situation in which endothelial dysfunction and abnormal angiogenesis are the leading disturbances. In fetuses with intrauterine growth retardation, a hypoxic environment secondary to uteroplacental insufficiency. In previous studies, increased levels of endocan in maternal blood samples have been shown. Although maternal blood can be a good reflector of situations both in fetuses and their mothers, measurement of endocan in umbilical cord blood samples may better represent the pathology in fetuses.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Van, Turkey
- Van Region Education and Training Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
For "intrauterine growth retardation" group:
- consent to participate study
- detection of intrauterine growth retardation during follow up of pregnancy
For "healthy fetuses" group:
- consent to participate study
- absence of intrauterine growth retardation during follow up of pregnancy
Exclusion Criteria:
- multiple pregnancy
- presence of major developmental anomalies of fetuses
- detection of chromosomal anomalies
- malnourished mothers
- vegetarian diet of mothers
- use of cigarette and alcohol during pregnancy
- previous history of stillbirths
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
intrauterine growth retardation
Blood samples are going to be taken from the umbilical cord of the fetuses.
Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
|
After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm.
The serum samples with specific identification numbers are going to be stored at -80 °C.
After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
|
healthy fetuses
Blood samples are going to be taken from the umbilical cord of healthy fetuses without intrauterine growth retardation.
Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
|
After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm.
The serum samples with specific identification numbers are going to be stored at -80 °C.
After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
endocan in umbilical cord blood
Time Frame: just after delivery of fetus at clamping of umbilical cord
|
levels of endothelial cell specific molecule 1 (ng/ml) in umbilical cord blood
|
just after delivery of fetus at clamping of umbilical cord
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Kucukbas GN, Kara O, Yuce D, Uygur D. Maternal plasma endocan levels in intrauterine growth restriction. J Matern Fetal Neonatal Med. 2022 Apr;35(7):1295-1300. doi: 10.1080/14767058.2020.1749591. Epub 2020 Apr 14.
- Lan X, Liu Z. Circulating endocan and preeclampsia: a meta-analysis. Biosci Rep. 2020 Jan 31;40(1):BSR20193219. doi: 10.1042/BSR20193219.
- Szpera-Gozdziewicz A, Kosicka K, Gozdziewicz T, Krzyscin M, Wirstlein P, Siemiatkowska A, Glowka F, Wender-Ozegowska E, Breborowicz GH. Maternal Serum Endocan Concentration in Pregnancies Complicated by Intrauterine Growth Restriction. Reprod Sci. 2019 Mar;26(3):370-376. doi: 10.1177/1933719118773480. Epub 2018 May 9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EndocanIUGR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrauterine Retardation
-
Poitiers University HospitalCompletedIntrauterine Growth Retardation (IUGR)France
-
Johns Hopkins UniversityWithdrawnFetal Growth Retardation | Intrauterine Growth Restriction | Intrauterine Growth Retardation | Fetal Growth Restriction
-
PfizerCompletedGrowth Disorders | Intrauterine Growth RetardationFrance
-
University of South FloridaCompleted
-
Boston Children's HospitalCompletedPrematurity | Intrauterine Growth RetardationUnited States
-
Assiut UniversityCompleted
-
Ain Shams UniversityUnknownIntrauterine Growth Restriction AsymmetricalEgypt
-
Assiut UniversityCompletedIntrauterine Growth Restriction (IUGR)
-
National Center for Research Resources (NCRR)Children's Hospital Medical Center, CincinnatiUnknownIntrauterine Growth RetardationUnited States
-
Novo Nordisk A/SCompletedFoetal Growth Problem | Small for Gestational AgeNetherlands
Clinical Trials on endocan in umbilical cord blood
-
Bundang CHA HospitalWithdrawn
-
Bundang CHA HospitalWithdrawnCerebral PalsyKorea, Republic of
-
MinYoung Kim, M.D.Completed
-
MinYoung Kim, M.D.CHA UniversityCompletedGlobal Developmental DelayKorea, Republic of
-
MinYoung Kim, M.D.Completed
-
MinYoung Kim, M.D.CompletedGlobal Developmental DelayKorea, Republic of
-
Guangdong Women and Children HospitalUnknownSafety Issues | Effect of DrugsChina
-
Guangdong Women and Children HospitalRecruitingSafety Issues;Effect of DrugsChina
-
New York Blood CenterTerminatedLymphoma | Leukemia | Myelodysplasia | Genetic Disease | Severe Aplastic AnemiaUnited States